All In Biotech

Drug Trial Radar · NCT06716606

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

514

Planned (sponsor's estimate)

Start

Dec 12, 2024

Primary completion

Sep 27, 2030

Study completion Oct 23, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
ICON plc
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the efficacy and safety of belimumab on reducing the decline in lung function in participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis (dcSSc-ILD) and interstitial lung disease associated with other connective tissue diseases (CTD-ILD), respectively. The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.

Conditions

  • Connective Tissue Diseases

Interventions

  • BelimumabDrug

    Belimumab will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse events (AEs), Adverse Event of Special Interest events (AESIs), and Serious Adverse Event (SAEs)Time frame: Up to approximately 5 years

Locations

41 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • GSK Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

  • GSK Investigational Site

    Santa Fe, Argentina · Recruiting

  • GSK Investigational Site

    Fitzroy, Victoria, Australia · Recruiting

  • GSK Investigational Site

    Beijing, China · Recruiting

  • GSK Investigational Site

    Beijing, China · Recruiting

  • GSK Investigational Site

    Chengdu, China · Recruiting

  • GSK Investigational Site

    Hangzhou, China · Recruiting

  • GSK Investigational Site

    Mianyang, China · Recruiting

  • GSK Investigational Site

    Shanghai, China · Recruiting

  • GSK Investigational Site

    Shanghai, China · Recruiting

  • GSK Investigational Site

    Shenyang, China · Recruiting

  • GSK Investigational Site

    Zhuzhou, China · Recruiting

  • GSK Investigational Site

    Toulouse, France · Recruiting

  • GSK Investigational Site

    Larissa, Greece · Recruiting

  • GSK Investigational Site

    Thessaloniki, Greece · Recruiting

  • GSK Investigational Site

    Poria – Neve Oved, Israel, Israel · Recruiting

  • GSK Investigational Site

    Aichi, Japan · Recruiting

  • GSK Investigational Site

    Gunma, Japan · Recruiting

  • GSK Investigational Site

    Hiroshima, Japan · Recruiting

  • GSK Investigational Site

    Hokkaido, Japan · Recruiting

  • GSK Investigational Site

    Tokushima, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Yamanashi, Japan · Recruiting

  • GSK Investigational Site

    Bucheon Kyunggi-Do, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

  • GSK Investigational Site

    Suwon Kyunggi-do, South Korea · Recruiting

  • GSK Investigational Site

    Yongsan-Ku Seoul, South Korea · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    VigoPontevedra, Spain · Recruiting

  • GSK Investigational Site

    Bilbao, Bizkaia, Spain · Recruiting

  • GSK Investigational Site

    Leeds, United Kingdom · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.